One of the best ways to spot potential opportunity is by tracking insiders.
After all, who knows the company better than an insider – the CEO, CFO, COO, officers, employees, and directors? If they’re buying a sizable number of shares, it’s often a good idea to start looking into why and perhaps follow them into the stock.
Here are a few stocks insiders have been buying most recently.
Bausch Health (SYM: BHC)
Billionaire investor John Paulson just bought 6,352,667 shares of pharmaceutical company, Bausch Health (BHC), paying about $35.90 a share between June 10 and 13.
He bought the oversold stock as it began to bounce from strong support at $4.50. Now up to $6.18, we’d like to see BHC test $7.50 initially.
Helping, Carl Icahn recently took a 34% stake in the company. This happened just days after Bausch Health adopted a “poison pill” to ward off takeovers.
Perpetua Resources (SYM: PPTA)
Paulson also bought 7.6 million more shares of mining stock, Perpetua Resources (PPTA) for $100 million. He paid $13.20 per share on June 16.
He bought the now oversold stock just after it gapped from about $18 to $13. The stock dropped after the company increased its bought deal offering to 24.62 million shares at $13.20 a share for $325 million in gross proceeds.
Proceeds will support its Stibnite Gold Project, which according to Seeking Alpha, “is projected to be one of the highest-grade open-pit gold mines in the U.S., with 4.8M oz of gold reserves, and is expected to produce ~450K oz/year of gold over its first four years of production.”
“The project also holds an antimony reserve estimated at 148M lbs., the only identified antimony reserve in the U.S. and one of the largest reserves outside of Chinese control; the project could meet 35% of U.S. antimony demand during its initial six years of production.”
J.M. Smucker (SYM: SJM)
Oversold shares of J.M Smucker (SJM) just saw E.L.F. Beauty CEO buy 1,050 shares for $100,900. This was after SJM posted adjusted EPS of $2.31, which was down 13% year over year, but ahead of estimates of $2.24. Net sales dropped 3% year over year to $2.1 billion – which was below analyst expectations of $2.19.
Not helping, “Management projected adjusted earnings to drop to a range of $8.50 to $9.50 a share in the current fiscal year, which ends April 2026, down from $10.12 a share in fiscal 2025. Net sales, meanwhile, are expected to rise 2% to 4%, a sharp slowdown from the 7% growth Smucker’s saw in fiscal 2025,” as reported by Barron’s.
Trending Now: Partner” with Elon Musk on Project Colossus… Before July 1st
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you…
To partner with Elon on what he believes will be the biggest AI project of the century…
Starting with as little as $500.
Click here to see how you could take a stake in Elon’s private company…
Without having connections in Silicon Valley or having to be an accredited investor.
Found this helpful? Share it with others.
Written by Ian Cooper